ubrogepant Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
calcitonin gene-related peptide receptor antagonists 5361 1374248-77-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ubrogepant
  • ubrelvy
Ubrogepant is a calcitonin gene-related peptide receptor antagonist.
  • Molecular weight: 549.55
  • Formula: C29H26F3N5O3
  • CLOGP: -4.62
  • LIPINSKI: 1
  • HAC: 8
  • HDO: 2
  • TPSA: 104.29
  • ALOGS: 2.93
  • ROTB: 5

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Dec. 23, 2019 FDA ALLERGAN

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

Pharmacologic Action:

None

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Migraine indication 37796009 DOID:6364

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.67 acidic
pKa2 11.49 acidic
pKa3 2.79 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
100MG UBRELVY ALLERGAN N211765 Dec. 23, 2019 RX TABLET ORAL Dec. 23, 2024 NEW CHEMICAL ENTITY
50MG UBRELVY ALLERGAN N211765 Dec. 23, 2019 RX TABLET ORAL Dec. 23, 2024 NEW CHEMICAL ENTITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Calcitonin gene-related peptide type 1 receptor GPCR ANTAGONIST Ki 10.20 IUPHAR DRUG LABEL

External reference:

IDSource
4039081 VANDF
C5228589 UMLSCUI
CHEMBL2364638 ChEMBL_ID
D10673 KEGG_DRUG
C000615620 MESH_SUPPLEMENTAL_RECORD_UI
9803 INN_ID
DB15328 DRUGBANK_ID
AD0O8X2QJR UNII
68748835 PUBCHEM_CID
10176 IUPHAR_LIGAND_ID
2268216 RXNORM
328458 MMSL
37856 MMSL
d09467 MMSL
018241 NDDF
838467004 SNOMEDCT_US
838488008 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
UBRELVY HUMAN PRESCRIPTION DRUG LABEL 1 0023-6498 TABLET 50 mg ORAL NDA 27 sections
UBRELVY HUMAN PRESCRIPTION DRUG LABEL 1 0023-6501 TABLET 100 mg ORAL NDA 27 sections